Sorry, you need to enable JavaScript to visit this website.
This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in Great Britain.
This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the UK and Ireland.
Report adverse events
BVY® ▼(bictegravir 50mg/ emtricitabine 200mg/ tenofovir alafenamide 25mg tablets) PI

Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page. BIKTARVY® is subject to additional monitoring ▼ in Great Britain; this requirement no longer applies in Ireland and Northern Ireland.

The 2024 annual BHIVA Spring Conference was held in Birmingham, packed with high-quality scientific talks and posters.

 

Here we present key data from Gilead-sponsored studies to support your educational needs and help improve patient care. 

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment Naïve and Experienced People With HIV: 3 Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort

Recorded: May 1st 2024

Duration: 2 mins

First presented: EACS 2023

 

Watch a brief animation on the results from BICSTaR, the real-world study of BIKTARVY® use in Canada, France and Germany, with data cut from August 2022.

 UK-BVY-0708 Date of preparation June 2024